1
|
Li BH, Ma H, Zhu J, Chen J, Dai YQ, Zhang XJ, Li HM, Wu CZ. Semisynthesis and anti-cancer properties of novel honokiol derivatives in human nasopharyngeal carcinoma CNE-2Z cells. J Enzyme Inhib Med Chem 2023; 38:2244694. [PMID: 37558230 PMCID: PMC10413922 DOI: 10.1080/14756366.2023.2244694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 07/31/2023] [Accepted: 07/31/2023] [Indexed: 08/11/2023] Open
Abstract
In this study, 21 new honokiol derivatives were synthesised, and their anti-cancer properties were investigated. Among these, compound 1g exhibited the most potent cytotoxic activity against human nasopharyngeal carcinoma CNE-2Z cells, human gastric cancer SGC7901 cells, human breast cancer MCF-7 cells, and mouse leydig testicular cancer I-10 lines with IC50 values of 6.04, 7.17, 6.83, and 5.30 μM, respectively. Compared to the parental compound, 1g displayed up to 5.18-fold enhancement of the cytotoxic effect on CNE-2Z cells. We further demonstrated that 1g inhibited cell growth, suppressed migration and invasion, and induced apoptosis of CNE-2Z cells by down-regulating HIF-1α, MMP-2, MMP-9, Bcl-2, Akt and up-regulating Bax protein levels. Transfection of CNE-2Z cells with HIF-1α siRNA reduced cell migration and invasion. In addition, in vivo experiments confirmed that 1g inhibited tumour growth in CNE-2Z cell-xenografted nude mice with low toxicity. Thus, our data suggested that 1g was a potent and safe lead compound for nasopharyngeal carcinoma therapy.
Collapse
Affiliation(s)
- Bo-Han Li
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
| | - Hui Ma
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
| | - Jing Zhu
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
| | - Jie Chen
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
| | - Yi-Qun Dai
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
- Anhui Province Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu, Anhui, China
| | - Xiao-Jing Zhang
- Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Hong-Mei Li
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
- Anhui Province Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu, Anhui, China
| | - Cheng-Zhu Wu
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
- Anhui Province Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu, Anhui, China
| |
Collapse
|
2
|
Luo S, Jiang Y, Anfu Zheng, Zhao Y, Wu X, Li M, Du F, Chen Y, Deng S, Chen M, Li W, Li X, Gu L, Sun Y, Xiao Z, Shen J. Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review. Front Pharmacol 2022; 13:1064661. [PMID: 36532768 PMCID: PMC9751339 DOI: 10.3389/fphar.2022.1064661] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Accepted: 11/18/2022] [Indexed: 09/15/2023] Open
Abstract
Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.
Collapse
Affiliation(s)
- Shuang Luo
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Department of Pharmacy, The Second People’s Hospital of Jiangyou, Mianyang, China
| | - Yu Jiang
- Department of Pharmacy, The People’s Hospital of Wusheng, Guang’an, China
| | - Anfu Zheng
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Yueshui Zhao
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Xu Wu
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Mingxing Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Fukuan Du
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Yu Chen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Shuai Deng
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Meijuan Chen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Wanping Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Xiaobing Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Li Gu
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Yuhong Sun
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| | - Zhangang Xiao
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Jing Shen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- South Sichuan Institute of Translational Medicine, Luzhou, China
| |
Collapse
|
3
|
The Protective Effect of miR-27-3p on Ischemia-Reperfusion-Induced Myocardial Injury Depends on HIF-1α and Galectin-3. J Cardiovasc Transl Res 2022; 15:772-785. [PMID: 35194735 DOI: 10.1007/s12265-021-10203-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 12/22/2021] [Indexed: 10/19/2022]
Abstract
Cardiac ischemia-reperfusion injury usually results in acute myocardial infarction (AMI). MiRNAs have been identified as key regulators of AMI. This study was carried out to investigate the effect of miR-27-3p on cardiomyocyte injury in AMI. CCK-8 and flow cytometry assays were used to evaluate cell viability and apoptosis. The expression levels of miR-27-3p, galectin-3, and hypoxia-inducible factor-1α were measured by qRT-PCR. The relationship among miR-27-3p, galectin-3, and HIF-1α was assessed by bioinformatics analysis and luciferase assay. The effects of miR-27-3p and/or galectin-3 and HIF-1α on the inhibition of cell viability and apoptosis induced by H/R were explored. The expression levels of apoptosis-related proteins were determined by Western blot analysis. The expression levels of miR-27-3p were reduced in both ischemia-reperfusion myocardium and HL-1 cells during hypoxia. Overexpression of miR-27-3p reduced I/R-induced myocardial injury, and HIF-1α can reduce this effect. H/R reduced the expression levels of miR-27-3p in HL-1 cardiomyocytes, and HIF1-α reduced this effect, indicating that HIF1-α could regulate the expression of miR-27-3p, and galectin-3 was a target of miR-27-3p. Finally, overexpression of galectin-3 reduced the protective effect of miR-27-3p on cardiomyocyte injury. The expression levels of HIF1-α were increased, and miR-27-3p was downregulated after AMI. HIF-1α promoted myocardial protection by upregulating miR-27-3p, and downregulation of miR-27-3p promoted myocardium cell injury by targeting galectin-3.
Collapse
|
4
|
Liu JJ, Liu XY, Nie JP, Jia MQ, Yu Y, Qin N, Duan HQ. Discovery of Antimetastatic Chiral Ionone Alkaloid Derivatives Targeting HIF-1α/VEGF/VEGFR2 Pathway. ChemMedChem 2021; 16:2130-2145. [PMID: 33755334 DOI: 10.1002/cmdc.202100072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 03/07/2021] [Indexed: 11/10/2022]
Abstract
Novel chiral ionone alkaloid derivatives were synthesized and their antimetastatic effects were evaluated in human breast cancer cells using chemotaxis assay. Compared with positive control LY294002, a PI3 K inhibitor, derivatives 10 a, 11 a, 11 c, 11 g, 11 j, 11 k and 11 w exhibited significant inhibitory effects against cancer cell migration. Especially, the IC50 for compound 11 g was as low as 0.035±0.004 μM. Further investigations on compound 11 g revealed that it could exert inhibitory effects on the adhesion, migration and invasion of MDA-MB-231 cells. The mechanisms for the antitumor metastatic effects of 11 g might be through the inhibition of HIF-1α/VEGF/VEGFR2/Akt pathway, which suppressed the downstream signaling molecules, including Akt1/mTOR/p70S6K and Akt2/PKCζ/integrin β1 pathways. Taken together, chiral ionone alkaloid derivative 11 g has the potential to be developed into an antitumor metastatic agent for breast cancer.
Collapse
Affiliation(s)
- Jing-Jing Liu
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China
| | - Xin-Yao Liu
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China
| | - Jiang-Ping Nie
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China
| | - Mei-Qi Jia
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China
| | - Yang Yu
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China
| | - Nan Qin
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China
| | - Hong-Quan Duan
- Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theragnostic), Tianjin Medical University, Tianjin, China.,Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
| |
Collapse
|
5
|
Li HM, Li B, Ma H, Sun X, Zhu M, Dai Y, Ma T, Huo Q, Wu CZ. Bishonokiol A Induces Multiple Cell Death in Human Breast Cancer MCF-7 Cells. Asian Pac J Cancer Prev 2020; 21:1073-1080. [PMID: 32334473 PMCID: PMC7445970 DOI: 10.31557/apjcp.2020.21.4.1073] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Indexed: 01/07/2023] Open
Abstract
OBJECTIVE A dimeric neolignan, bishonokiol A (BHNKA) isolated from Magnolia grandiflora, significantly inhibits the proliferation of human breast cancer cells. However, the exact mechanism of BHNKA induced breast cancer cell death is unknown. In this study, we investigated the pharmacological mechanism underlying BHNKA induced MCF-7 cell death. METHODS Cell viability measurement was performed by the MTT assay. Flow cytometry with PI staining, DAPI staining, and electron microscopy were used to analyze cellular death modes. In addition, western blotting, siRNA transfection, ATP assay, and fluorescence microscopy were used to determine the mechanism of BHNKA induced MCF-7 cell death. RESULTS BHNKA induced cell death by apoptosis, necroptosis and autophagy at the same concentration and time in MCF-7 cells, and electron microscopy confirmed these results. The mechanism of BHNKA triggered apoptosis and autophagy in MCF-7 cells was primarily due to an increase in the Bax/Bcl-2 ratio and simultaneous up-regulation of LC3-II protein expression, respectively. BHNKA induced necroptosis by activation of the RIP1-RIP3-MLKL necroptosis cascade, up-regulation of cyclophilin D (CypD) protein expression to stimulate ROS generation. We further demonstrated that siRNA-mediated down-regulation of CypD protected against BHNKA induced cell death. CONCLUSIONS These results suggest that BHNKA may be a potential lead compound for development as an anti-breast cancer agent for induction of multiple cell death pathways.
Collapse
Affiliation(s)
- Hong-Mei Li
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Bohan Li
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Hui Ma
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Xiaolong Sun
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Meilin Zhu
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Yiqun Dai
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Tao Ma
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Qiang Huo
- School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| | - Cheng-Zhu Wu
- Department of Medicinal Chemistry, School of Pharmacy, Bengbu Medical University, 2600 Donghai Road, Bengbu, Anhui, China
| |
Collapse
|
6
|
Zhang J, Wang Q, Wang Q, Guo P, Wang Y, Xing Y, Zhang M, Liu F, Zeng Q. Chrysophanol exhibits anti-cancer activities in lung cancer cell through regulating ROS/HIF-1a/VEGF signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 2019; 393:469-480. [PMID: 31655854 DOI: 10.1007/s00210-019-01746-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Accepted: 09/27/2019] [Indexed: 12/12/2022]
Abstract
In the present study, we explored the anti-tumor and anti-angiogenesis effects of chrysophanol, and to investigate the underlying mechanism of the chrysophanol on anti-tumor and anti-angiogenesis in human lung cancer. The viability of cells was measured by CCK-8 assay, cell apoptosis was measured by Annexin-FITC/PI staining assay, and the cell migration and invasion were analyzed by wound-healing assay and transwell assay. ROS generation and mitochondrial membrane potential were analyzed by DCFH-DA probe and mitochondrial staining kit. Angiogenesis was analyzed by tube formation assay. The expression of CD31 was analyzed by immunofluorescence. The levels of proteins were measured by western blot assay. The anti-tumor effects of chrysophanol in vivo were detected by established xenograft mice model. In this study, we found that the cell proliferation, migration, invasion, tube formation, the mitochondrial membrane potential, and the expression of CD31 were inhibited by chrysophanol in a dose-dependent manner, but cell apoptotic ratios and ROS levels were increased by chrysophanol in a dose-dependent manner. Furthermore, the effects of chrysophanol on A549, H738, and HUVEC cell apoptotic rates were reversed by the ROS inhibitor NAC. Besides, the effects of chrysophanol on HUVEC cell tube formation were reversed by the HIF-1α inhibitor KC7F2 and the VEGF inhibitor axitinib in vitro. Moreover, tumor growth was reduced by chrysophanol, and the expression of CD31, CD34, and angiogenin was suppressed by chrysophanol in vivo. Our finding demonstrated that chrysophanol is a highly effective and low-toxic drug for inhibition of tumor growth especially in high vascularized lung cancer.
Collapse
Affiliation(s)
- Jie Zhang
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Qian Wang
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China.,Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China
| | - Qiang Wang
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Peng Guo
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Yong Wang
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Yuqing Xing
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Mengmeng Zhang
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Fujun Liu
- Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, Shandong, China
| | - Qingyun Zeng
- Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China.
| |
Collapse
|
7
|
Zhang L, Qi X, Zhang G, Zhang Y, Tian J. Saxagliptin protects against hypoxia-induced damage in H9c2 cells. Chem Biol Interact 2019; 315:108864. [PMID: 31629700 DOI: 10.1016/j.cbi.2019.108864] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 10/02/2019] [Accepted: 10/14/2019] [Indexed: 12/19/2022]
Abstract
Type II diabetes is recognized as a major risk factor for death due to cardiovascular complications such as coronary heart disease (CHD), but the complex interplay between these two diseases remains poorly understood. Suppression of oxidative stress, apoptosis, and inflammation of endothelial cells is a valuable treatment strategy to prevent or halt the progression of CHD. In the present study, we used real-time polymerase chain reaction (PCR), Western blot analysis, and enzyme linked immunosorbent assay (ELISA) to investigate the effects of saxagliptin on hypoxia-inducible factors. Our findings demonstrate that saxagliptin can significantly improve cell viability in H9c2 cells as well as reduce hypoxia-induced oxidative damage and loss of mitochondrial membrane potential. Saxagliptin reduced hypoxia-induced NADPH oxidase 4 (NOX 4). We also show that saxagliptin can reduce the expression of matrix metallopeptidase-2 (MMP-2) and matrix metallopeptidase-9 (MMP-9), two important degradative enzymes. Saxagliptin also suppressed hypoxia-induced expression of high mobility group box-1 protein (HMGB1), a key inflammatory cytokine. Finally, we show that saxagliptin can exert atheroprotective effects by reducing the expression of myeloid differential protein-88 (MyD88) and increasing the expression of nuclear factor erythroid-2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). Thus, saxagliptin shows promise as a treatment against diabetes-associated CHD.
Collapse
Affiliation(s)
- Lili Zhang
- Department of Cardiology, The People's Hospital of Longhua, Shenzhen, 518109, China.
| | - Xiaogui Qi
- Department of Cardiology, The People's Hospital of Longhua, Shenzhen, 518109, China
| | - Guowei Zhang
- Department of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
| | - Yingying Zhang
- Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China
| | - Jiali Tian
- Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China
| |
Collapse
|